Vasculitis & polymyalgia rheumatica
Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis
Authors' conclusion
IFX was effective and relatively safe for p-NBS.
Study context
- Population
- Patients with parenchymal neuro-Behçet's syndrome (p-NBS)
- Participants
- 77 patients8 studies
- Outcome
- Pooled clinical response (complete and partial remission) and MRI improvement
- Follow-up
- Months 3, 6, and 12
Methodological detailsretrospective, single-institution case series
- Retrospective
- Single-institution case series
Pooled result
As reported in the abstract
Clinical response (pooled) · 3, 6 and 12 months
- Clinical response at 3 months
- 97% (95% CI 61.9-100%)
- Clinical response at 6 months
- 89.6% (95% CI 45.9-100%)
- Clinical response at 12 months
- 100% (95% CI 96.0-100%)
- Radiological improvement at 3 months
- 100% (95% CI 89.7-100%)
- Radiological improvement at 6 months
- 89.1% (95% CI 26.3-100%)
- Radiological improvement at 12 months
- 99.5% (95% CI 96.0-100%)
Further pooled results
Response in institutional case series (n=11)
- Complete remission
- 1
- Partial remission
- 10
Safety
- Severe adverse events observed in 7 patients
Original publication
Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis. Clin Exp Rheumatol. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →